# OnCo record syndax (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/syndax/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "syndax" ;
  schema:name "Syndax Pharmaceuticals"@en ;
  schema:description "Syndax Pharmaceuticals, of Waltham, Massachusetts, developed revumenib (Revuforj), the first menin inhibitor approved for leukaemia, proved in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation. It also makes axatilimab for chronic graft-versus-host disease, and resistance mutations in menin itself are the class's unsolved problem."@en ;
  schema:url <https://onco.cc/companies/syndax/>, <https://www.syndax.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.syndax.com> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/epigenetics/> ;
  onco:drugs <https://onco.cc/drugs/revumenib/> ;
  onco:trials <https://onco.cc/trials/nct07211958/> .